Skip to main content
FDA expands indication of Novo Nordisk's Victoza
6/18/2019

The FDA has approved Novo Nordisk's Victoza, or liraglutide, injection for use in patients 10 to 17 years of age with type 2 diabetes. The drug was previously approved for adults with the condition.

Full Story: